The novel FRLRS prognostic signature regulated could be found in tumor and immune-related pathways, including cytokine-receptor interaction, glycerophospholipid metabolism, homologous recombination, IgA production, primary immunodeficiency, endometrial cancer, peroxisome, propanoate metabolism, prostate cancer, valine leucine, and isoleucine degradation (Supplementary Table S6). This evidence concerns the gene CD79A and inborn error of immunity.